Norway: Targovax agrees terms on NOK300m convertible bond

Targovax, a clinical-stage immuno-oncology company developing immune activators to target solid tumours, has agreed terms on a financing of up to gross NOK300m (US$29.5m) with Atlas Special Opportunities via a three-year convertible bond facility. Atlas Special Opportunities is a joint venture investment vehicle created by London-based investment fund Atlas Capital Markets and Arena Investors, a…

You must be a HMI Subscriber to view this content.

Subscribe Now »